Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.61 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.61 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | GRAMD1A | Q96CP6 | 5/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29260150 | 1.00 | CRBN (0.61) | CRBNDDB1STAT3EGFRGRAMD1A | |
| SCHEMBL22276597 | 0.94 | CRBN (0.66) | CRBNDDB1STAT3EGFRGRAMD1A | |
| SCHEMBL31240354 | 0.93 | CRBN (0.61) | CRBNDDB1STAT3GRAMD1AIRAK4 | |
| SCHEMBL30526101 | 0.93 | CRBN (0.61) | CRBNDDB1STAT3GRAMD1AIRAK4 | |
| SCHEMBL22276652 | 0.89 | DDB1 (0.65) | CRBNDDB1STAT3EGFRGRAMD1A | |
| SCHEMBL30135923 | 0.89 | CRBN (0.51) | CRBNDDB1STAT3EGFRIRAK4 | |
| SCHEMBL20442798 | 0.88 | DDB1 (0.69) | CRBNDDB1STAT3EGFRGPR119 | |
| SCHEMBL24420973 | 0.88 | CRBN (0.71) | CRBNDDB1STAT3GPR119 | |
| SCHEMBL29614567 | 0.88 | CRBN (0.71) | CRBNDDB1STAT3GPR119 | |
| SCHEMBL28909815 | 0.88 | DDB1 (0.68) | CRBNDDB1STAT3EGFRGRAMD1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885STAT3 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.